Abstract
Type 2 diabetes mellitus (T2DM) is a major challenge to healthcare systems around the world, with an estimated prevalence of 6% (246 million) in 2007 rising to 7.3% (380 million) in 2025 worldwide.1-5 In this article, the authors consider the significance of the GLP-1 path-way in the management of T2DM, and some of the advantages of incretin-based therapy.
| Original language | English |
|---|---|
| Pages (from-to) | 18-28 |
| Number of pages | 11 |
| Journal | Future Prescriber |
| Volume | 9 |
| Issue number | 3 |
| DOIs | |
| Publication status | Published - 2008 |
UN SDGs
This output contributes to the following UN Sustainable Development Goals (SDGs)
-
SDG 3 Good Health and Well-being
Keywords
- diabetes
- medical care
- non-insulin-dependent diabetes
- glucose
- metabolism
Fingerprint
Dive into the research topics of 'Management of type 2 diabetes : the GLP-1 pathway'. Together they form a unique fingerprint.Cite this
- APA
- Author
- BIBTEX
- Harvard
- Standard
- RIS
- Vancouver